KAT5 is Dual-Function Therapeutic Target with Direct Antitumor and Immunomodulatory Activity in Endometrial Cancer.

KAT5 overexpression in endometrial cancer is linked to poor patient outcomes and its inhibition suppresses tumor growth and enhances immune responses.

• Why it matters: Targeted therapies for endometrial cancer are limited, and understanding epigenetic regulators like KAT5 could reveal new treatment strategies that improve patient prognosis.
• What they did: Researchers identified KAT5 as overexpressed in EC and used silencing and pharmacological inhibition with NU9056 in cell lines, organoids, and mouse models to assess its role in tumor growth and immune activation.
• The result: Inhibiting KAT5 reduced tumor progression, disrupted cytoskeletal dynamics, increased genomic instability, activated immune pathways, and improved immune cell infiltration, suggesting KAT5 as a dual-function therapeutic target.